Volume 65, Issue 3, Pages (March 2004)

Slides:

Advertisements

Similar presentations

Atrial Fibrillation Findings in the LIFE Trial

Advertisements

1 Downloaded from The L osartan I ntervention F or E ndpoint reduction in hypertension study An investigator-initiated, prospective,

1 The L osartan I ntervention F or E ndpoint reduction in hypertension study An investigator-initiated, prospective, community-based, multinational, double-blind,

51st Annual Scientific Session for the LIFE Investigators

Introduction The American Journal of Medicine

Volume 65, Issue 3, Pages (March 2004)

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Volume 79, Issue 2, Pages (January 2011)

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients G.A. Block, P. Raggi, A. Bellasi, L. Kooienga,

Volume 67, Issue 6, Pages (June 2005)

The effect of hypertension on the risk for kidney cancer in Korean men

Volume 9, Issue 4, Pages (April 2012)

Volume 57, Issue 5, Pages (May 2000)

John P. Middleton, Patrick H. Pun Kidney International

Volume 73, Issue 5, Pages (March 2008)

Need for better diabetes treatment for improved renal outcome

Volume 79, Pages S9-S13 (April 2011)

Volume 81, Issue 3, Pages (February 2012)

Steven G. Coca, Swathi Singanamala, Chirag R. Parikh

Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease Johannes F.E. Mann, Qi-Long.

Progression of diabetic nephropathy

Volume 84, Issue 5, Pages (November 2013)

Methotrexate in the urine

A new era in phosphate binder therapy: What are the options?

Volume 68, Issue 5, Pages (November 2005)

Renal risk scores: Progress and prospects

Volume 79, Issue 9, Pages (May 2011)

Volume 87, Issue 2, Pages (February 2015)

Pieter Evenepoel, Björn K. Meijers Kidney International

U-shaped effect of eGFR and mortality

Volume 83, Issue 4, Pages (April 2013)

Volume 70, Issue 12, Pages (December 2006)

Volume 67, Pages S48-S51 (January 2005)

Volume 65, Issue 6, Pages (June 2004)

Amit X. Garg, William F. Clark, R. Brian Haynes, Andrew A. House

Volume 81, Issue 6, Pages (March 2012)

Volume 73, Issue 12, Pages (June 2008)

Structure, not just function

Volume 85, Issue 3, Pages (March 2014)

Volume 76, Issue 3, Pages (August 2009)

Volume 65, Issue 4, Pages (April 2004)

Does reducing salt intake increase cardiovascular mortality?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Proteinuria and hypertensive nephrosclerosis in African Americans

Presentation of the 2003 Jean Hamburger Award to Robert W. Schrier

The kidney, a cardiovascular risk marker, and a new target for therapy

Volume 80, Issue 6, Pages (September 2011)

Volume 87, Issue 1, Pages (January 2015)

Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis N.-Y. Zalunardo, C.-L. Rose, I.W.Y.

Volume 85, Issue 5, Pages (May 2014)

Volume 65, Issue 4, Pages (April 2004)

Quality of life in peritoneal dialysis patients: Decline over time and association with clinical outcomes Sr. Anne B. Bakewell, Rob M. Higgins, Mair.

Homocysteine, renal function, and risk of cardiovascular disease

Folkert W. Asselbergs, Hans L. Hillege, Wiek H. Van Gilst

Volume 67, Pages S55-S62 (January 2005)

Cardiovascular risk assessment in kidney transplantation

Volume 74, Issue 11, Pages (December 2008)

Michael R. Lattanzio, Matthew R. Weir Kidney International

Cardiovascular risk in chronic kidney disease

Charles A. Herzog Kidney International

Areef Ishani, Allan J. Collins, Charles A. Herzog, Robert N. Foley

Volume 67, Issue 5, Pages (May 2005)

Volume 75, Issue 7, Pages (April 2009)

Changes to the End-Stage Renal Disease Quality Incentive Program

Volume 76, Issue 5, Pages (September 2009)

WASH—World Action on Salt and Health

Stephen Pastan, J. Michael Soucie, William M. McClellan

Volume 79, Issue 10, Pages (May 2011)

Volume 56, Issue 5, Pages (November 1999)

Presentation transcript:

Volume 65, Issue 3, Pages 1041-1049 (March 2004) The impact of serum uric acid on cardiovascular outcomes in the LIFE study Aud Høieggen, Michael H. Alderman, Sverre E. Kjeldsen, Stevo Julius, Richard B. Devereux, U.L.F. de Faire, Frej Fyhrquist, Hans Ibsen, Krister Kristianson, Ole Lederballe-Pedersen, Lars H. Lindholm, Markku S. Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Cong Chen, Björn Dahlöf, for the LIFE Study Group Kidney International Volume 65, Issue 3, Pages 1041-1049 (March 2004) DOI: 10.1111/j.1523-1755.2004.00484.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Serum uric acid and cardiovascular risk per 10 μmol/L. Hazard ratios for composite cardiovascular outcome (stroke, myocardial infarction, and cardiovascular deaths) in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study related to baseline serum uric acid levels. When adjusted for Framingham risk score, the hazard ratios remained statistically significant only in women. Kidney International 2004 65, 1041-1049DOI: (10.1111/j.1523-1755.2004.00484.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Serum uric acid on treatment and cardiovascular risk per 10 μmol/L. Hazard ratios for composite cardiovascular outcome (stroke, myocardial infarction, and cardiovascular deaths) in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study related to on-treatment serum uric acid levels. Kidney International 2004 65, 1041-1049DOI: (10.1111/j.1523-1755.2004.00484.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Serum uric acid by treatment group and gender. The increase in serum uric acid throughout the study was significantly attenuated in the losartan compared to the atenolol-treated group. (A) Overall population (P < 0.0001). (B) Men (P < 0.0001). (C) Women (P < 0.0001). Year 0 refers to baseline. Kidney International 2004 65, 1041-1049DOI: (10.1111/j.1523-1755.2004.00484.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Hemoglobin level by treatment group and gender. Hemoglobin decreased during the study and the decline was more pronounced in the losartan group than in the atenolol group. The differences in delta values were similar for men and women. (A) Overall population. (B) Men. (C) Women. Year 0 refers to baseline. Kidney International 2004 65, 1041-1049DOI: (10.1111/j.1523-1755.2004.00484.x) Copyright © 2004 International Society of Nephrology Terms and Conditions